Pathstone Family Office’s Charles River Laboratories CRL Stock Holding History

Pathstone Family Office’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$604K	Buy	3,082 +360	+13%	+$73.9K	﹤0.01%	952
2023 Q2	$578K	Buy	2,722 +902	+50%	+$179K	0.01%	695
2023 Q1	$385K	Sell	1,820 -3,512	-66%	-$796K	0.01%	802
2022 Q4	$891K	Buy	5,332 +147	+3%	+$32.1K	0.01%	841
2022 Q3	$1.02M	Buy	+5,185	New	+$1.12M	0.01%	723
2021 Q3	–	Sell	-638	Closed	-$236K	–	870
2021 Q2	$236K	Buy	+638	New	+$213K	0.01%	719
2021 Q1	–	Sell	-2	Closed	–	–	810
2020 Q4	$0	Hold	2	–	–	﹤0.01%	1184
2020 Q3	$0	Sell	2 -2	-50%	-$415	﹤0.01%	830
2020 Q2	$0	Buy	+4	New	+$638	﹤0.01%	763
2018 Q2	–	Sell	-15	Closed	-$1K	–	196
2018 Q1	$1K	Buy	+15	New	+$1.62K	﹤0.01%	343
2017 Q2	–	Sell	-12	Closed	-$1K	–	441
2017 Q1	$1K	Buy	+12	New	+$1.02K	﹤0.01%	446

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Pathstone Family Office's CRL Position: Q3 2023 in Review

Pathstone Family Office increased its Charles River Laboratories (CRL) stake by 13% in Q3 2023, buying an estimated $73.9K and bringing the position to 3,082 shares worth $604K. The position accounts for ﹤0.01% of the portfolio, ranked #952.

Pathstone Family Office first reported a position in CRL in Q1 2017 and has held it in 11 quarters since. The position peaked at $1.02M in Q3 2022. 622 funds tracked by Wall St. Rank hold CRL as of Q3 2023.

Pathstone Family Office held 3,082 shares of Charles River Laboratories worth $604K as of Q3 2023.
Pathstone Family Office bought 360 Charles River Laboratories shares in Q3 2023, an estimated $73.9K.
Charles River Laboratories made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #952 holding.
Pathstone Family Office first reported a position in Charles River Laboratories in Q1 2017 and has held it in 11 quarters since.
Pathstone Family Office's Charles River Laboratories position peaked at $1.02M in Q3 2022.
622 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.